Examkin

Question

Difficulty: Very hardPharmacological and Parenteral Therapies

While managing a client in the intensive care unit who is in profound distributive shock, the nurse notes the client has developed severe, unsafe psychomotor agitation. The client's only vascular access is a single-lumen central venous catheter (CVC) currently infusing norepinephrine at 0.2 mcg/kg/min0.2 \text{ mcg/kg/min} to maintain a mean arterial pressure greater than 65 mm Hg65 \text{ mm Hg}. The provider prescribes a stat dose of intravenous (IV) midazolam 2 mg2 \text{ mg}. Which of the following is the safest and most appropriate action for the nurse to take?

  1. Establish an alternative peripheral or intraosseous intravenous access site to administer the prescribed midazolam.Answer
  2. B
    Verify the chemical compatibility of midazolam and norepinephrine, then slowly administer the midazolam through the Y-site port closest to the client.
  3. C
    Pause the norepinephrine infusion, flush the CVC briskly with 10 mL of 0.9% sodium chloride, administer the midazolam, and resume the infusion.
  4. D
    Dilute the midazolam in 20 mL of normal saline and infuse it via a syringe pump connected to the CVC to maintain a precise, steady flow rate.

Answer

Establish an alternative peripheral or intraosseous intravenous access site to administer the prescribed midazolam.
The correct answer is to establish an alternative access site. Pushing any medication, flushing, or adding a secondary flow to a single-lumen line that is actively infusing a life-sustaining, highly concentrated vasopressor is extremely dangerous. Any of these actions will rapidly force the vasopressor residing in the catheter's dead space into the systemic circulation, causing a potentially fatal hypertensive crisis. A completely dedicated line is absolutely required.

Step-by-Step Solution

1
Analyze the client's current vascular access and ongoing therapies.
The client possesses only a single-lumen CVC which is actively infusing a life-sustaining, highly concentrated vasopressor (norepinephrine).
Recognizing the physical limitations of the existing access is the foundational step in parenteral safety.
2
Evaluate the pharmacokinetic properties and flow dynamics of the continuous infusion.
Norepinephrine has a half-life of 1-2 minutes. The catheter's dead space is currently filled with this potent medication at a high concentration.
Guides the decision-making process regarding the physiological impact of altering the line's flow rate or interrupting therapy.
3
Determine the physical impact of administering a secondary medication via the existing single lumen.
Pushing a medication, flushing the line, or adding a concurrent infusion will forcefully displace the norepinephrine residing in the dead space into the client's circulation, causing speed shock and a hypertensive crisis.
Identifies the lethal mechanical flaw in utilizing the existing line.
4
Select the safest alternative for administration.
A completely separate vascular access point must be established for the stat medication.
Prevents inadvertent bolusing and ensures uninterrupted delivery of the life-sustaining vasopressor therapy.

Key Concept

Continuous vasoactive infusions (like norepinephrine) must be administered through a dedicated line or dedicated multilumen port. Manipulating the line (flushing, pushing, or piggybacking) alters the flow rate and inadvertently boluses the highly concentrated medication residing in the catheter dead space into the client, leading to severe hemodynamic instability.
Rate this question

Topics

Pharmacological and Parenteral Therapies

More questions from this topic